Sionna Therapeutics posts higher-than-expected Q3 net loss on restructuring costs
SION•Sionna Therapeutics reported a Q3 net loss of $32.42 million, above the $28.22 million consensus estimate, as development and restructuring costs lifted expenses. It cut its workforce by 46%, plans to start a Phase 2 cystic fibrosis trial in early 2027 and expects cash to fund operations into the second half of 2029.
1. Quarterly results and plans
Sionna Therapeutics’ Q3 net loss widened to $32.42 million, missing analyst expectations of $28.22 million. Operating expenses were $34.82 million, driven by research and development and restructuring costs, including a 46% workforce reduction. The company is focusing resources on its SION-451 and SION-2222 combination for cystic fibrosis, plans to start its AscenSION CF Phase 2 trial in the first quarter of 2027 and expects its cash position to fund operations into the second half of 2029.
